Cannell & Spears LLC Reduces Bristol Myers Squibb Holdings

Institutional investor cuts stake in pharmaceutical company by 6.7%

Mar. 15, 2026 at 10:36am

Got story updates? Submit your updates here. ›

Cannell & Spears LLC, an institutional investor, has reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 6.7% in the third quarter, according to a recent SEC filing. The firm now owns 252,914 shares of the biopharmaceutical company's stock, valued at $11.41 million.

Why it matters

This filing provides insight into the investment strategies of Cannell & Spears LLC and their view on the prospects of Bristol Myers Squibb, a major pharmaceutical company. Changes in institutional ownership can signal shifts in market sentiment around a stock.

The details

Cannell & Spears LLC sold 18,177 shares of Bristol Myers Squibb in the third quarter, reducing its total position to 252,914 shares. The firm's holdings in the company were valued at $11.41 million as of the most recent filing.

  • Cannell & Spears LLC reduced its Bristol Myers Squibb holdings in the 3rd quarter of 2026.

The players

Cannell & Spears LLC

An institutional investor that manages a portfolio of investments, including shares in Bristol Myers Squibb.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

This filing indicates that Cannell & Spears LLC has reduced its exposure to Bristol Myers Squibb, potentially signaling a shift in the firm's investment strategy or outlook on the pharmaceutical company's prospects. Investors may want to monitor any further changes in institutional ownership of Bristol Myers Squibb stock.